Abstract
The author critiques the expedient application of market valuation principles by the transnational corporations and other large firms in the Indian pharmaceutical industry on a number of issues like patents, pricing, irrational drugs, clinical trials, etc. He contends that ethics in business is chiseled and etched within the confines of particular social structures of accumulation. An ascendant neo-liberal social structure of accumulation has basically shaped these firms' sharp opposition to the Indian Patents Act, 1970, government administered pricing, etc. The author contends that the practice of neo-liberal economics is strongly associated with a "one dimensional" ethics that privileges market valuation principles over all others. This seems to inevitably generate a social counter-movement that struggles for social protections. He critiques neo-liberal business practices from a perspective that derives from the work of the economic anthropologist Karl Polanyi. Before the present phase of liberalization in India, markets were "managed", but without a "welfare state" in place. Moving toward deregulation of the markets without a welfare state in place is unethical. Keeping the debilities of the institutional framework of public policy in mind, the author adopts a Polanyian perspective that places its trust and hope in the growing social legitimacy of the counter-movement in opposition to both neo-liberal business practices and the degenerate behavior of state agencies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bal, A.: 1997, ‘Consumer Protection Act and Medical Profession’, in A. Jesani et al. (eds.), Market, Medicine and Malpractice (Center for Enquiry into health and Allied Themes, Mumbai), pp. 139–152.
Balance, R. et al.: 1992, The World's Pharmaceutical Industry: An International Perspective on Innovation, Competition and Policy (Prepared for the United Nations Industrial Development Organization, Edward Elgar, Aldershot, UK).
Beer, S.: 1969, British Politics in the Collectivist Age (Vintage Books, New York).
Carroll, A. B.: 1991, ‘The Pyramid of Social Responsibility: Toward the Moral Management of Organizational Stakeholders’, Business Horizons (July-August), 39–48.
CEHAT: 2000, Ethics in the Social Sciences and Health Research: Draft Code of Conduct (Center for Enquiry into Health and Allied Themes, Mumbai).
Chandrasekhar, C. P. and P. Purkayastha: 1982, ‘Transfer Pricing in the Indian Drug Industry: An Estimate and its Implications’, Social Scientist, No. 194 ( January).
Chaudhuri, S.: 1984, ‘Indigenous Firms in Relation to the Transnational Corporations in the Drug Industry in India’, Unpublished doctoral dissertation, Jawaharlal Nehru University, New Delhi.
Chaudhuri, S.: 1993, ‘Dunkel Draft on Drug Patents: Background and Implications’, Economic & Political Weekly (September 4), 1861–1865.
Chaudhuri, S.: 1999, ‘Growth and Structural Change in the Pharmaceutical Industry in India’ (Indian Institute of Management, Calcutta, Working Paper, WPS-356/99), May.
Chowdhury, Z.: 1995, The Politics of Essential Drugs and the Making of a Successful Health Strategy: Lessons from Bangladesh (Vistaar Publications, New Delhi), pp. 1–25.
Chetley, A.: 1990, A Healthy Business? (Zed Books, London).
Correa, C. M.: 2000, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (Zed Books, London and Third World Network, Penang, Malaysia).
D'Mello, B.: 1997, ‘Underdevelopment After the Uruguay Round: India’, in J. M. Griesgraber and B. G. Gunter (eds.), Rethinking Bretton Woods: World Trade-Toward Fair and Free Trade in the Twenty-first Century (Pluto Press, London and Chicago, IL), pp. 54–76.
FRCH: 1997, Health Care in India: A Profile (The Foundation for Research in Community Health, Mumbai and Pune), pp. 39–111.
Fusfeld, D. R.: 1994, ‘The Market in History’, Monthly Review 45(1) (May), 1–7.
GOI: 1975, Report of the Committee on Drugs and Pharmaceutical Industry (Chairman: Jaisukhlal Hathi; Ministry of Petroleum and Chemicals, Government of India), April.
Kasper, W. and M. E. Streit: 1998, Institutional Economics: Social Order and Public Policy (Edward Elgar, Cheltenham, U.K.).
Keayla, B. K.: 1992, TRIPS Patent System: Analysis and Implications (National Working Group on Patent Laws, New Delhi).
Lanjouw, J. O.: 1998, ‘The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?’ (NBER Working Paper No. W6366), January.
Marcelis, C. and M. Shiva: 1986, ‘EP Drugs: Unsafe by Any Name’, in Kathleen McDonnell (ed.), Adverse Effects: Women and the Pharmaceutical Industry (International Organization of Consumer Unions, regional Office for Asia and the Pacific, Penang, Malaysia), pp. 11–26.
McChesney, R. W.: 1999, ‘Introduction’, in N. Chomsky (ed.), Profit Over People: Neo-Liberalism and the Global Order (Madhyam Books, New Delhi), pp. 7–16.
Melrose, D.: 1982, Bitter Pills: Medicines and the Third World Poor (Oxfam, Oxford, printed by Policy Research for Development Alternative, 1985).
Phadke, A. R.: 1995, ‘Need versus Supply of Drugs’, Economic & Political Weekly (September 17), 2454–2458.
Phadke, A.: 1998, Drug Supply and Use: Towards a Rational Drug Policy (Sage Publications, New Delhi).
Polanyi, K.: 1944, The Great Transformation: The Political and Economic Origins of Our Times (Beacon, Boston, MA).
Porter, M. E.: 1985, Competitive Advantage: Creating and Sustaining Superior Performance (The Free Press, New York).
Ramachandran, R.: 2000, ‘For a Mission Approach’, Frontline 17(15) ( July 22-August 4), 89–92.
Rane, W.: 1993, ‘Rising Drug Prices’, Economic & Political Weekly (April 17), 743–746.
Rane, W.: 1994, ‘Dangerous Drugs’, Economic & Political Weekly (October 1), 2587–2588.
Rane, W.: 1998, ‘Price Control on Drugs is Essential’, Economic & Political Weekly (October 17–24), 2697–2698.
Rane, W.: 1995, ‘Drug Prices: Sharp Rise After Decontrol’, Economic & Political Weekly (November), 2977–2980.
Rawls, J.: 1971, A Theory of Justice (Harvard University Press, Cambridge, MA).
Sathyamala, C.: 2000, An Epidemiological Review of the Injectable Contraceptive, Depo-Provera (Medico Friend Circle & Forum for Women's Health, India).
Sen, A.: 1999, Development As Freedom (Alfred Knopf, New York).
Spinello, R. A.: 1992, ‘Ethics, Pricing and the Pharmaceutical Industry’, Journal of Business Ethics 11, 617–626.
Szecsi, M.: 1979, ‘Looking Back on the Great Transformation’, Monthly Review 30 (January), 34–45.
Tullock, G.: 1986, ‘Public Choice’, in J. Eatwell et al. (eds.), The New Palgrave: A Dictionary of Economics (Macmillan, London).
VHAI: 1996, Banned and Bannable Drugs (authored by Mira Shiva and Wishvas Rane, for the Voluntary Health Association of India, New Delhi).
WTO: 1994, The Results of the Uruguay Round of Multilateral Trade Negotiations: The Legal Texts (World Trade Organization, Geneva), pp. 365–399.
Zaveri, N. B.: 1998, Patents for Medicine: Balanced Patent Law the Need of the Poor (Indian Drug Manufacturers Association, Mumbai).
Zdanowicz, J. S. et al.: 1995, ‘Capital Flight from India to the United States Through Abnormal Pricing in International Trade’, Finance India (September).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
D'Mello, B. Transnational Pharmaceutical Corporations and Neo-Liberal Business Ethics in India. Journal of Business Ethics 36, 165–185 (2002). https://doi.org/10.1023/A:1014234119562
Issue Date:
DOI: https://doi.org/10.1023/A:1014234119562